CCO Independent Conference Coverage
From Podium to Practice: Clinical Impact of New Data From EASL 2011
FACULTY:
- Graham R. Foster, FRCP, PhD
- Paul Y. Kwo, MD
- Stefan Zeuzem, MD
19 Capsule Summaries
Expert Analysis
|
2011 Annual Meeting of the European Association for the Study of the Liver*
March 30-April 3, 2011 | Berlin, Germany
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Mouse over track for more info
|
CCO Slideset
Highlights From Berlin 2011
 |
|
Nezam H. Afdhal, MD, FRCPI and Paul Martin, MD, highlight key data on HCV new agents, hepatitis B, nonviral hepatitis, and advanced liver disease from the 2011 EASL meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.52 MB
| Date posted: 4/22/2011
|
Follow us...
Follow CCO Hepatitis on Twitter
CCO Hepatitis will be tweeting throughout the conference. Watch for the Twitter hashtag #CCOEASL to keep up with all the action from Berlin!
Click here to start following us today.
|
Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
Addition of Alisporivir to PegIFN/RBV Yields Superior Efficacy vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV
The addition of alisporivir to pegIFN/RBV therapy was generally well tolerated but was associated with higher rates of hyperbilirubinemia vs pegIFN/RBV alone; cases of hyperbilirubinemia resolved early during treatment and were not associated with evidence of hepatotoxicity.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|
|